The Evolving Role of Succinate in Tumor Metabolism: An 18 F-FDG–Based Study
Philippe Garrigue, Aurore Bodin-Hullin, Laure Balasse, Samantha Fernandez, Wassim Essamet, Françoise Dignat-George, Karel Pacak, Benjamin Guillet, David Taieb

To cite this version:
Philippe Garrigue, Aurore Bodin-Hullin, Laure Balasse, Samantha Fernandez, Wassim Essamet, et al.. The Evolving Role of Succinate in Tumor Metabolism: An 18 F-FDG–Based Study: succinate and [18F]-FDG.. Journal of Nuclear Medicine, Society of Nuclear Medicine, 2017, 58 (11), pp.1749-1755. <10.2967/jnumed.117.192674>. <hal-01770170>

HAL Id: hal-01770170
https://hal-amu.archives-ouvertes.fr/hal-01770170
Submitted on 24 Apr 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The evolving role of succinate in tumor metabolism: an $^{18}$F-FDG-based study

Philippe Garrigue$^{1,2,3}$, Aurore Bodin-Hullin$^3$, Laure Balasse$^{1,2}$, Samantha Fernandez$^2$, Wassim Essamet$^4$, Françoise Dignat-George$^1$, Karel Pacak$^5$, Benjamin Guillet$^{1,2,3}$, David Taïeb$^{2,3}$

1Aix-Marseille Univ, Inserm, UMR-S 1076, Marseille, France.
2Aix-Marseille Univ, CERIMED, Marseille, France.
3Department of Nuclear Medicine, Aix-Marseille Univ, Marseille, France.
4APHM Timone Department of Neuropathology, Marseille, France.
5Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, 20892 USA.

Abbreviated title: succinate and $^{18}$F-FDG.

Key Terms: succinate, $^{18}$F-FDG, succinate dehydrogenase, paraganglioma, tricarboxylic acid cycle

Total word count: 2984

Table(s): 0

Figure(s): 3
Suppl figure: 3

Corresponding author:

David Taïeb, MD, PhD

Department of Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, 264 rue Saint-Pierre, 13385 Marseille, France,

Email: david.taieb@ap-hm.fr, Phone/FAX: +33 (0) 4-91-38-44-06.
Abstract

**Objective.** In recent years, inherited and acquired mutations in the TCA cycle enzymes have been reported in diverse cancers. Pheochromocytomas and paragangliomas (PPGLs) often exhibit dysregulation of glucose metabolism which is also driven by mutations in genes encoding the TCA cycle enzymes or by activation of hypoxia signaling. PPGLs associated with succinate dehydrogenase (SDH) deficiency are characterized by high $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) avidity. This association is currently only partially explained. Therefore, we hypothesized that accumulation of succinate due to the TCA cycle defect could be the major connecting hub between $SDH$-mutated tumors and $^{18}$F-FDG uptake profile.

**Design.** To test whether succinate modifies the $^{18}$F-FDG metabolic profile of tumors, we performed *in vitro* and *in vivo* (microPET/CT imaging and autoradiography) experiments in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in different cell models. As control, we also evaluated the impact of succinate on $^{18}$F-fluorocholine uptake and retention. GLUT1 immunohistochemistry was performed to assess whether $^{18}$F-FDG uptake was correlated with GLUT1 staining.

**Results.** Intratumoral injection of succinate significantly increased $^{18}$F-FDG uptake at 24 hours on microPET/CT imaging and autoradiography. No effect of succinate was observed on cancer cells *in vitro*, but interestingly, we found that succinate caused increased $^{18}$F-FDG uptake by Human Umbilical Vein Endothelial Cells (HUVEC) in a concentration dependent manner. No significant effect was observed after intratumoral injection of fumarate or PBS. Succinate, fumarate, and PBS have no effect on cell viability, regardless of cell lineage. Intramuscular injection of succinate also significantly increases $^{18}$F-FDG uptake by muscle when compared to
either PBS or fumarate, highlighting the effect of succinate on connective tissues. No difference was observed between PBS and succinate on \(^{18}\text{F}\)-fluorocholine uptake in the tumor and muscle and on hind limb blood flow. GLUT1 expression quantification did not significantly differ between the study groups.

**Conclusions.** The present study shows that succinate stimulates \(^{18}\text{F}\)-FDG uptake by endothelial cells, a finding which partially explains the \(^{18}\text{F}\)-FDG metabotype observed in tumors with SDH deficiency. Although this study is an \(^{18}\text{F}\)-FDG based approach, it provides an impetus to better characterize the determinants of \(^{18}\text{F}\)-FDG uptake in various tumors and their surrounding microenvironment with a special emphasis on the role of tumor specific oncometabolites.
Introduction

Succinate (succinic acid in blood pH) has only been considered for many decades as an intermediate metabolite of the tricarboxylic acid (TCA) cycle. During aerobic respiration, succinate is oxidized to fumarate, donating reducing equivalents. The reaction is catalyzed by succinate dehydrogenase (SDH), an enzyme complex located in the inner mitochondrial membrane that participates in both the TCA cycle and electron transport chain. SDH is composed of four nuclearly encoded subunits whose structure and genes have mostly been conserved through evolution. Hans Adolf Krebs team noticed some intermediates, including succinate, could accumulate in the interstitial space during liver ischemia (1). During ischemia, succinate can be produced by reduction of fumarate (a purine nucleotide cycle metabolite) via the reverse action of SDH. Succinate is then secondarily secreted from the cells into the blood stream (2).

Many studies have shown that succinate has several functions beyond participating in the TCA cycle, of which some are mediated via a G protein-coupled succinate receptor (GPR91) (3). Through GPR91, succinate may have hormone-like actions in blood cells as well as fat, liver, heart, retina, and kidney tissues (4). For instance, in response to retinal ischemia, succinate plays an important role in the development of new blood vessels via GPR91 and subsequent modulation of VEGF release by retinal ganglion neurons (5).

Beyond cell functions described above, succinate and a few other TCA cycle intermediates were found to contribute to carcinogenesis (6). Recently, germline and somatic mutations in an additional three TCA cycle enzymes, fumarate hydratase (FH), malate dehydrogenase type 2 (MDH2), and isocitrate dehydrogenase (IDH) were identified in diverse cancers, which suggest metabolic alterations as the underlying hallmark of cancer. These mutations cause disruption of the TCA cycle and accumulation of TCA cycle intermediates,
ultimately altering various functions and the epigenome of cancer cells. These so-called oncometabolites were found to act as competitors of 2-oxoglutarate-dependent dioxygenases, which are involved in a broad spectrum of pathways such as hypoxic response, immune system dysfunction, and epigenetic reprogramming (7).

Pheochromocytomas and paragangliomas (PPGL) are tumors associated with TCA cycle defects (8). The most common cause of hereditary PPGL is SDH deficiency and accumulation of highly elevated levels of succinate. These tumors, unlike IDH-mutants tumors (9), are highly glucose avid (8). This metabolic pattern has been demonstrated by $[^{18}F]$-fluorodeoxyglucose ($[^{18}F]$-FDG) positron emission tomography (PET) imaging studies (10). This finding is attributed to activation of hypoxia signaling (8) and is in discordance with several experimental studies that have failed to identify increased glycolysis (11-15). Interestingly, neuroblastoma cell lines (a neural-crest tumor model similar to PPGL) with $SDHB$ mutations were even found to have a paradoxical decrease in glucose uptake compared to wild-type cells, despite an increased growth rate and invasiveness (16). These effects were even more pronounced in the presence of human fibroblasts in co-culture experiments, indicating a possible metabolic cooperation between stroma and cancer cells (17). Primary human fibroblasts exhibit an increased glucose uptake when they are co-cultured with wild-type cells, and an even greater uptake when co-cultured with $SDHB$-silenced neuroblastoma cell lines. Several studies have shown that yeast with $sdhA$ mutations may aberrantly efflux succinate from the mitochondria (18-20), and are therefore succinate is likely to act as an extracellular ligand. This efflux of succinate is also presumed in humans due to $SDH$-related PPGL patients have a higher value of plasma succinate-to-fumarate ratio compared to apparently sporadic and Neurofibromatosis type 1 ($NF1$) patients (21). Therefore, we hypothesized that succinate could be the connecting hub between $SDH$ deficiency and tumor $[^{18}F]$-FDG uptake profile via paracrine action on stroma cells.
Materials and Methods

Cells

Human umbilical vascular endothelial cells (HUVECs) are commonly used as a laboratory model system for studying the pathophysiology of endothelial cells (22) and tumor-stroma interactions (23). HUVECs were cultured in T175 plates in Endothelial Growth Medium-2 (EGM2, Lonza) supplemented with 10% decomplemented fetal calf serum (FCS) at 37°C under 5% carbon dioxide (CO₂).

HT-29 is a human colorectal adenocarcinoma-derived cell line (obtained from a primary tumor). These cells were chosen because they have been fully characterized from an oncogenetic, metabolomics, and functional imaging standpoint. They are characterized by an activation of the mitogen-activated protein kinase pathway due to BRAF mutations (24), absence of succinate accumulation (25), and a moderate avidity for [18F]-FDG (26, 27). HT-29 cells were cultured in T175 plates in Dulbecco’s Modified Eagle Medium (DMEM, Lonza) supplemented with 10% FCS at 37°C under 5% CO₂.

Primary human cardiac fibroblasts (HCF, PromoCell) were cultured in T175 plates in Fibroblast Growth Medium 3 (PromoCell) supplemented with 10% FCS at 37°C under 5% CO₂.

In vitro [18F]-FDG uptake by endothelial, tumor cells, and fibroblasts

HT-29 cells, HUVECs, and primary human cardiac fibroblasts were transferred to 6-well flasks and pretreated for 24 hours with 0.01, 0.1, 1.0, or 10 nmol of succinate (Sigma-Aldrich) or fumarate (Sigma-Aldrich) per μL of culture medium. Fumarate or succinate solutions were prepared at 1 mmol/L, pH 7.4, in PBS. HT-29 cells allowed us to overcome the potential local
self-secretion of succinate by tumor cells that could prevaricate any exogenous succinate impact on $^{18}$F-FDG tissue uptake. Phosphate Buffer Saline (PBS) was used as a control. PBS was used as control. Each condition was repeated in triplicate. $^{18}$F-FDG was added (2 MBq/well) for 20 min, then the cells were washed three times with PBS, lysed with NaOH 0.2 M, and counted on COBRA-2 Auto gamma-counter (Packard). Counting results were corrected by physical decay $^{18}$F and expressed as mean normalized $^{18}$F-FDG uptake.

**In vitro evaluation of cell viability**

Cell viability was assessed by counting with Trypan blue on KOVA slides after a 24 hour incubation with 0.01 nmol/µL or 10 nmol/µL of fumarate or succinate, and then compared to PBS treatment. Counting results were expressed as mean normalized number of viable cells.

**Mice**

All procedures using animals were approved by the Institution’s Animal Care and Use Committee (CE14, Aix-Marseille Université) and were conducted according to the EU Directive 2010/63/EU and the recommendations of the Helsinki Declaration. Six-week-old BALB/c mice ($n=12$) and Hsd:AthymicNude-Foxn1nu mice ($n=15$) were purchased from Envigo. Animals were housed in enriched cages, placed in a temperature-and hygrometry-controlled room with daily monitoring, and fed with water and a commercial diet ad libitum.

**Xenograft model**
HT-29 cells ($10^7$) were trypsinized and re-suspended in 500 µL of complete medium (Dulbecco’s Modified Eagle Medium, 10% fetal calf serum, 100 U/mL penicillin, and 100 µL Matrigel Basement Membrane Matrix High Concentration (Corning). Animals were then allowed to rest for 2 weeks. A first group of 3 Hsd:AthymicNude-Fox1*nu* mice was subcutaneously injected with $10^6$ HT-29 cells/100 µL on the right and left shoulders and on the right flank. A second group of 6 Hsd:AthymicNude-Fox1*nu* mice was subcutaneously injected with $10^6$ HT-29 cells/100 µL on the right shoulder with $10^6$ HT-29 cells. A third group of 6 Hsd:AthymicNude-Fox1*nu* mice was subcutaneously injected the same way with $10^6$ HT-29 cells/100 µL on the right shoulder with $10^6$ HT-29 cells.

In vivo $[^{18}F]$-FDG uptake following intratumoral injection of succinate

Fourteen days after tumor engraftment, the xenografted mice from the first group were injected with 10 µL of a 1 nmol/µL succinate solution in the right shoulder tumor with 10 µL of a 1 nmol/µL fumarate solution in the left shoulder tumor, and with 10 µL PBS in the right hind limb tumor every 6 hours for 24 hours under 1.5% isoflurane anesthesia ($n=3$). $[^{18}F]$-FDG injection (5-10 MBq/50 µL, i.p.) was performed 3 hours after the last succinate injection.

PET images were acquired 40 min after injection on a Mediso NanoPET/CT under 1.5% isoflurane anesthesia. ROI quantification was performed on reconstructed PET/CT images, corrected by a tumor volume and pondered by animal weight.

At the end of the procedure, animals were euthanized with a lethal dose of pentobarbital, and the tumors were then explanted, stored in PFA4%, sliced, and directly exposed for 30 seconds to medium-sensitive phosphorimaging plates. Signals were analyzed by densitometry using Cyclone Plus® (Perkin-Elmer). Image analysis and quantifications were performed on
In vivo dynamic $^{18}$F-FDG and $^{18}$F-fluorocholine uptake following intratumoral injection of succinate

Fourteen days after tumor engraftment, the xenografted mice from the second group were injected with a 1 nmol/µL succinate solution or with PBS (10 µL in the tumor, $n=3$ per condition) every 6 hours for 24 hours under 1.5% isoflurane anesthesia. $^{18}$F-FDG injection (5-10 MBq/50µL, i.v.) was performed 3 hours after the last succinate injection. The xenografted mice from the third group were injected with a 1 nmol/µL succinate solution or with PBS (10 µL in the tumor, $n=3$ per condition), every 6 hours for 24 hours under 1.5% isoflurane anesthesia. $^{18}$F-fluorocholine injection (5-10 MBq/50µL, i.v.) was performed 3 hours after the last succinate injection. PET images were acquired beginning with the injection on a Mediso NanoPET/CT camera under 1.5% isoflurane anesthesia. PET images were reconstructed in dynamic mode with 10 frames of 1 minute, then 6 frames of 5 minutes followed by one 20-minutes frame. ROI quantification was performed on PET/CT images, corrected by a tumor volume.

In vivo dynamic $^{18}$F-FDG and $^{18}$F-fluorocholine uptake following intramuscular injections of succinate

Twelve BALB/c mice were injected in the right quadriceps femoris muscle with succinate (10µL from a 1 nmol/µL solution) and in the left quadriceps femoris muscle with fumarate (10µL...
from a 1 nmol/µL solution, “Fumarate/Succinate group”, \( n=6 \) or with PBS (“PBS/Succinate group”, \( n=6 \)).

\(^{18}\)F-FDG and \(^{18}\)F-fluorocholine injections (5-10 MBq/50µL, i.v.) were performed on different groups 3 hours after the last succinate injection. PET images were acquired beginning with the injection on a Mediso NanoPET/CT camera under 1.5% isoflurane anesthesia. PET images were reconstructed in dynamic mode with 10 frames of 1 minutes, 6 frames of 5 minutes followed by one 20-minutes frame.

LASER-Doppler perfusion imaging (Perimed) was used to assess hind limb blood flow as previously described (28), right after the \(^{18}\)F-FDG acquisition (\( n=3 \) per condition). Results were expressed as a ratio of succinate-treated limb to PBS- or fumarate-treated limb blood flow.

**Immunohistochemistry**

To assess whether the increased uptake was due to GLUT1 overexpression after succinate treatment, GLUT1 immunohistochemistry (GLUT-1, Rabbit Polyclonal Antibody, Thermo Scientific, RB-9052-P, dilution 1:200) was performed on HT-29 tumors and HUVECs treated with succinate, fumarate, or PBS. The immunoreactivity of GLUT1 was visually scored by a pathologist blinded to the study groups.

**Statistics**

Comparison of *in vitro* cellular uptake and cell viability were analyzed by 1-way ANOVA with *post-hoc* Bonferroni test. *In vivo* uptake of \(^{18}\)F-FDG and \(^{18}\)F-fluorocholine in muscles
and tumors and LASER-Doppler data were compared by two-tailed Mann-Whitney test. A $P$ value of $<0.05$ indicated statistical significance.

Results

**Succinate increases tumor [${}^{18}\text{F}$]-FDG uptake and retention in vivo**

To test whether succinate modifies the [${}^{18}\text{F}$]-FDG metabolic pattern profile of tumors, we performed intratumoral injection of succinate in xenografts tumors. As a control, we also evaluated the effects when PBS and fumarate were injected. Tumor uptake was analyzed by microPET/CT imaging and autoradiography. Intratumoral injections of succinate significantly increased [${}^{18}\text{F}$]-FDG uptake at 24 hours on microPET/CT ($P=0.0014$, $n=3$, **Fig. 1A**, Suppl Fig 1) and autoradiography ($P=0.0124$, $n=3$, **Fig. 1B**). Autoradiography resolution did not allow us to discriminate the effects of succinate in the different compartments *in vivo*. To test whether tracer uptake was linked to glucose metabolism and not related to increased blood flow or increased capillary permeability induced by succinate, we performed head-to-head comparison between [${}^{18}\text{F}$]-FDG and [${}^{18}\text{F}$]-Fluorocholine on dynamic µPET/CT. Intratumoral injections of succinate induced a significant increase in [${}^{18}\text{F}$]-FDG uptake by tumors compared to the animals treated with PBS ($P<0.0096$, $n=3$, **Fig. 1C**) but no significant change in [${}^{18}\text{F}$]-fluorocholine uptake was observed in both groups ($P=0.6088$, $n=3$, **Fig. 1D**).

*Succinate increases [${}^{18}\text{F}$]-FDG uptake by endothelial cells, but not in tumor cells or*
Intramuscular injections of succinate induced a significant increase in $^{18}\text{F}$-FDG uptake by fumarate ($P=0.0458$, $n=3$, Fig. 3A). Intramuscular injection of succinate did not affect $^{18}\text{F}$-FDG uptake by fibroblasts in vitro ($P=0.0023$, $n=3$). Compared to fumarate, succinate significantly increased $^{18}\text{F}$-FDG uptake by HUVECs at concentrations of 0.1 ($P=0.0125$, $n=3$), 1.0 ($P=0.0028$, $n=3$), and 10 nmol/µL ($P=0.0008$, $n=3$). No significant effect was observed at 0.01 nmol/µL of succinate (Fig. 2). Succinate slightly, but not significantly, decreased $^{18}\text{F}$-FDG uptake by HT-29 cells and fibroblasts. No matter the cell lineage, total number of live cells was not significantly affected by the presence of succinate when compared to fumarate and PBS.

Succinate increases in vivo $^{18}\text{F}$-FDG uptake and retention by connective tissue

To test whether a modification in uptake pattern of connective tissue could produce the changes on PET imaging, we evaluated the effects of intramuscular administration of succinate in mice. Intramuscular injections of succinate induced a significant increase in $^{18}\text{F}$-FDG uptake by muscle compared to the contralateral muscle injected with either PBS ($P=0.0162$, $n=3$) or fumarate ($P=0.0458$, $n=3$, Fig. 3A). Intramuscular injection of succinate did not affect $^{18}\text{F}$-fluorocholine uptake compared to the contralateral muscle injected with either PBS ($P=0.6173$, $n=3$) or fumarate ($P=0.92303$, $n=3$, Fig. 3B). Finally, no difference on hind limb blood flow was
observed on LASER-Doppler ($P=1.000$, $n=3$ and $P=0.7500$, $n=3$ respectively, Fig. 3C).

GLUT1 Immunohistochemistry

GLUT1 expression quantification did not significantly differ between study groups in HUVECs or HT-29 tumors (in both epithelial and stromal compartments) (Suppl Fig 2 and 3).
Discussion

It is now evident that succinate should not only be viewed as a metabolite donor in the TCA cycle, but also as a signaling molecule with hormone-like functions, which could play a vital role during various pathophysiological conditions such as ischemia (4) and inflammation (29). The identification of cancer-associated mutations in the TCA cycle enzymes has also highlighted the prevailing notion that aberrant metabolic function can contribute to carcinogenesis via a broad spectrum of pathways such as hypoxic, inflammation and immune system responses, and epigenetic reprogramming (30, 31). Succinate has been shown to stabilize HIF- via inhibition of prolyl hydroxylases in the cytosol, suggesting a mechanistic link between SDHx mutations, high tumor vascularity, and $[^{18}\text{F}]-\text{FDG}$ uptake profile in absence of $\text{VHL}$ mutations (12, 32). Although this hypothesis is appealing, it should probably be applied to all tumors. Furthermore, the metabolic impact of a malfunctioning TCA is partially compensated by the activation of several alternative pathways that can provide metabolites that can enter the TCA at various checkpoints (15, 33).

It is well understood that the quantification of tumor $[^{18}\text{F}]-\text{FDG}$ uptake by PET imaging can be hampered by the contribution of the metabolized $[^{18}\text{F}]-\text{FDG}$ fraction located within stroma cells. Additionally, the un-metabolized component of $[^{18}\text{F}]-\text{FDG}$ (in the blood within a tumor, in the intercellular spaces, and within the tumor and stroma cells themselves) can also be far from negligible in certain circumstances. During the past 10 years, studies have shown that $\text{SDHx}$-PPGLs exhibit highly elevated $[^{18}\text{F}]-\text{FDG}$ uptake. Recently, we have shown in a small series that high standardized uptake value (SUV) values can be observed in PPGL despite relative low $k_3$ values (the rate constant for $[^{18}\text{F}]-\text{FDG}$ phosphorylation) compared to malignancies which exhibit high $k_3$ values (34). This finding suggested that increased $[^{18}\text{F}]-\text{FDG}$ uptake cannot be
We also demonstrated that succinate-induced $^{18}$F-FDG uptake was not due to increased blood flow or increased capillary permeability since this phenomenon was not observed after injection of $[^{18}$F]-Fluorocholine and no increased blood flow was observed on LASER-Doppler. The concentrations used throughout this study (0 to 10 nmol/µL) were previously identified as appropriate by metabolomics studies which did not distinguish intra from extracellular succinate components. Many studies have shown that SDH mutated tumors contain enormous levels of succinate (35-38) that could even be detected by in vivo MR spectroscopy (39, 40). It is probable that large amounts of succinate are effluxed by the mutated cells. Analyses of compartmentalized levels of TCA cycle metabolites have revealed that yeast with sdhΔ mutations may aberrantly efflux succinate from the mitochondria to the cytosol (18). Other studies have even reported that succinate could be excreted into the medium during cultivation of yeast sdhΔ mutants (19, 20). It has been speculated that this retrograde pathway may prevent the potential detrimental effects of succinate excess on non-mitochondrial processes (41). Succinate can migrate through the mitochondrial and plasma membrane via different transport systems such as a succinate-fumarate transporter in the inner mitochondrial membrane, porins in the outer mitochondrial membrane, and a sodium-independent anion exchanger in the plasma membrane.

The present study shows a new hypothesis based on the effect of succinate on $[^{18}$F]-FDG uptake by endothelial cells, expanding its repertoire of extracellular functions. This could partially explain the $[^{18}$F]-FDG uptake pattern observed in PPGLs, which are highly vascularized tumors. We also demonstrated that succinate-induced $^{18}$F-FDG uptake was not due to increased blood flow or increased capillary permeability since this phenomenon was not observed after injection of $[^{18}$F]-Fluorocholine and no increased blood flow was observed on LASER-Doppler. The present study shows that endothelial cells may play an important role in $[^{18}$F]-FDG uptake, and perhaps in some tumors, they significantly contribute to a final $[^{18}$F]-FDG PET image. This finding will provide incentive to better characterize the molecular mechanisms involved in increased $[^{18}$F]-FDG uptake in various tumors, including PPGLs TCA cycle defects.
Unfortunately, due to the lack of a well-characterized human PPGL cell line, further validation is not yet possible. The present results also suggest that tumor microenvironment plays an extraordinary role in supplying energy and metabolic fuel for a tumor cell (42, 43). Notably, the increased glucose uptake in endothelial cells is not due to increased GLUT1 expression. However, this could be due to the involvement of other glucose transporters and/or increased activity of intracellular hexokinases (44). Finally, it would be interesting to use GPR91 antagonists or nitric oxide (NO) signaling modulation to study the signaling pathway involved in succinate-induced glucose uptake by endothelial cells (45, 46). If so, this concept could propose a novel therapeutic approach on starving PPGL via inhibition of GPR91 or NO signaling.
References


**Legends**

**Figure 1**

A: *(top)* Representative PET/CT images of HT-29 tumor-bearing mice (*n*=3) 40 minutes after [18F]-FDG injection (5-10 MBq/50 µL, i.p.) and 27 hours after the first 10 µL-intratumoral injection of 1 mM succinate (right shoulder, red arrow), 1 mM fumarate (left shoulder, green arrow), or PBS (right hind limb, yellow arrow) every 6 hours for 24 hours. *(bottom)* Quantification from [18F]-FDG microPET/CT in tumors. **P<0.01** (One-way ANOVA with Bonferroni post-hoc test, *n*=3 per condition).

B: *(top)* Representative autoradiographic images of HT-29 tumors extracted from mice right after the microPET/CT imaging *(bottom)*. Quantification from tumor autoradiography. *P<0.05* (One-way ANOVA with Bonferroni post-hoc test, *n*=3 per condition).

C: *(top)* Representative microPET/CT images of mice hind limbs (*n*=3) 40 minutes after [18F]-FDG injection (5-10 MBq/50µL, i.v.) and 27 hours after the first succinate or PBS injection every 6 hours for 24 hours. Bottom graph shows corresponding quantifications expressed in % of the injected dose per gram of tissue over time, from dynamic microPET/CT reconstruction. **P<0.01** (Mann-Whitney test, *n*=3 per condition).

D: *(top)* Representative microPET/CT images 40 minutes after [18F]-fluorocholine injection (5-7 MBq/50µL, i.v.) and 27 hours after the first succinate or PBS injection every 6 hours for 24 hours. Bottom graph shows corresponding quantifications expressed in % of the injected dose.
per gram of tissue over time, from dynamic microPET/CT reconstruction. (Mann-Whitney test, \( n=3 \) per condition).

**Figure 2**

Influence of succinate pretreatment on \([^{18}\text{F}]-\text{FDG}\) uptake in HUVEC\(\text{s}\) (A, top), in HT-29 cells (B, top) and in primary cardiac fibroblasts (C, top) after pretreatment for 24 hours with 0, 0.01, 0.1, 1.0, or 10 nmol of succinate per \(\mu\text{L}\) of culture medium. *\( P<0.05\), **\( P<0.01\), ***\( P<0.001\) (2-way ANOVA with Bonferroni post-hoc test, \( n=3 \) per condition).

Viability of HUVEC\(\text{s}\) (A, bottom), HT-29 cells (B, bottom) and fibroblasts (C, bottom) by counting on KOVA slides with Trypan blue after a 24 hour incubation with 0.01 nmol/\(\mu\text{L}\) or 10 nmol/\(\mu\text{L}\) of fumarate or succinate, compared to PBS treatment (2-way ANOVA with Bonferroni post-hoc test, \( n=3 \) per condition).

**Figure 3**

A: Representative microPET/CT images of mice hind limbs (\( n=3 \)) 40 minutes after \([^{18}\text{F}]-\text{FDG}\) injection (5-10 MBq/50\(\mu\text{L}\), i.v.) and 27 hours after the first succinate (right hind limb) or fumarate or PBS (left hind limb) injection every 6 hours for 24 hours. Bottom graph shows corresponding quantifications in each hind limb expressed in % of the injected dose per gram of tissue over time, from dynamic microPET/CT reconstruction. *\( P<0.05\) (Mann-Whitney test, \( n=3 \) per condition).
B: Representative microPET/CT images of mice hind limbs (n=3) 40 minutes after $[^{18}F]$-fluorocholine injection (5-7 MBq/50µL, i.v.) and 27 hours after the first succinate (right hind limb) or fumarate or PBS (left hind limb) injection every 6 hours for 24 hours. Bottom graph shows corresponding quantifications in each hind limb expressed in % of the injected dose per gram of tissue over time, from dynamic microPET/CT reconstruction. (Mann-Whitney test, n=3 per condition).

C: Representative LASER-Doppler perfusion images of mice hind limbs (n=6), right after $[^{18}F]$-FDG PET (28 hours after the first succinate (right hind limb) or fumarate or PBS (left hind limb) injection every 6 hours for 24 hours. Bottom graphs show corresponding quantifications of the perfusion signal in each hind limb.